MedPath

Effect of Mother's Supplementation Omega-3 in the Dynamics of Fetal Ductus Arteriosus: a Randomized Clinical Trial.

Not Applicable
Conditions
Pregnancy
Interventions
Dietary Supplement: Omega 3
Dietary Supplement: Soy Oil
Registration Number
NCT02565290
Lead Sponsor
Instituto de Cardiologia do Rio Grande do Sul
Brief Summary

The effect of anti-inflammatory substances on the dynamics of the fetal ductus arteriosus is well documented, but the anti-inflammatory property of polyunsaturated fatty acid omega-3 about changing this dynamic is not established. This study evaluate the relationship between supplementation of omega-3 in the dynamics of the fetal ductus arteriosus in the third trimester. Women with gestational between 28 to 32 weeks will receive capsules of omega-3 or placebo, to be consumed daily for 3 weeks.

Detailed Description

The omega-3 features similar the statins to be antioxidants and anti-inflammatory drugs and their derivatives have the function of slowing the neuro-inflammation, oxidative stress and apoptotic cell death anti-inflammatory properties. Also, they have antithrombotic effects, being related to prevent disease. Studies show that supplementation with omega-3 has a positive impact on several outcomes like cardiovascular disease, asthma, rheumatoid arthritis and Alzehimer. Objective: Evaluate the relationship between supplementation of omega-3 in the dynamics of the fetal ductus arteriosus in the third trimester. Methodology: randomized double blind clinical trial. Women with gestational age between 28 to 32 weeks, literate, over 18 years will be invited. Pregnant women with anti-inflammatory drugs, they have a higher intake of dietary polyphenols to 127mg / day or using drugs that may interfere with the absorption of omega-3 are excluded. The selected women will be randomized to receive capsules of omega-3 or placebo, to be consumed daily for 3 weeks. In the first interview, and after 3 weeks, they will respond the Questionnaire Food Frequency (QFF) to quantify polyphenols and omega 3 in their diet, weight and height will be measured and the examination of fetal echocardiography is performed.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
74
Inclusion Criteria

Women between 28 - 32 weeks pregnancy who accept participate in the study.

Exclusion Criteria

hypertensive , diabetic , who use anti-inflammatory drugs , HIV positive , do not take mate, black or green tea, had inflammation in the last 5 days, allergic to fish or soy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Omega-3Omega 32 capsules of omega 3 - 2 times a day
Soy oilSoy Oil2 capsules of soy oil - 2 times a day
Primary Outcome Measures
NameTimeMethod
Pulsatility index of fetal ductus arteriosus28 to 32 weeks of pregnancy

The measure will be collected before and after 21 days of supplementation with omega 3 capsules

Secondary Outcome Measures
NameTimeMethod
Biomarkers of oxidative stress28 to 32 weeks of pregnancy

Will be collected blood before and after 21 days of supplementation with omega 3

Systolic and diastolic velocity of fetal ductus arteriosus28 to 32 weeks of pregnancy

The measure will be collected before and after 21 days of supplementation with omega 3

Inflammatory biomarkers (interleukins, prostaglandins, cyclooxygenase)28 to 32 weeks of pregnancy

Will be collected blood before and after 21 days of supplementation with omega 3

Trial Locations

Locations (1)

Paulo Zielinsky

🇧🇷

Porto Alegre, RS, Brazil

© Copyright 2025. All Rights Reserved by MedPath